
Shares in TRLS, suspended since May after heavy losses, face cancellation from AIM on 5 October 2026 unless a new nominated adviser is appointed, leaving shareholders facing a total wipeout.
The company is still seeking a buyer for its US subsidiary, Trellus Health Inc, though it has warned shareholders not to expect any return even if a sale succeeds.